1. Show article details.

    Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

    Business Wire – 7:00 AM ET 05/19/2022

    Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. This press release features multimedia. “We are very pleased to welcome Arun to our Board,” said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger.

  2. Show article details.

    Schrödinger to Present at Citi Biotech Virtual Co-Panel Day

    Business Wire – 8:30 AM ET 05/13/2022

    Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at the Citi Biotech Virtual Co-Panel Day.

  3. Show article details.

    BRIEF-Schrödinger Reports First Quarter 2022 Financial Results

    Reuters – 5:35 PM ET 05/04/2022

    Schrodinger Inc (SDGR): * SCHRÖDINGER REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * COMPANY MAINTAINS FULL-YEAR 2022 FINANCIAL OUTLOOK. * QTRLY TOTAL REVENUE$48.7 MILLION VERSUS $32.1 MILLION. * IND SUBMISSION FOR SGR-1505, SCHRÖDINGER'S MALT1 INHIBITOR, ON-TRACK FOR FIRST HALF OF 2022.

  4. Show article details.

    Schrödinger Reports First Quarter 2022 Financial Results

    Business Wire – 4:01 PM ET 05/04/2022

    Software Revenue of $33.1 Million, a 26 Percent Increase Over First Quarter of 2021; Total Revenue of $48.7 Million, up 51 Percent Over First Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Internal Pipeline Progressing, With IND Submission for SGR-1505, Schrödinger’s MALT1 Inhibitor, On-Track for First Half of 2022 NEW YORK---- Schrödinger, Inc., whose physics-based soft...

  5. Show article details.

    Schrödinger to Announce First Quarter 2022 Financial Results on May 4

    Business Wire – 8:30 AM ET 04/20/2022

    Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2022 financial results on Wednesday, May 4, 2022, after the financial markets close. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar.

  6. Show article details.

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 8:30 AM ET 04/19/2022

    Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 101,715 shares of the company’s common stock to 30 newly hired employees, including six newly hired employees based in India and one newly hired employee base...

  7. Show article details.

    Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List

    PR Newswire – 9:20 PM ET 04/12/2022

    SHANGHAI, April 12, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Since 2001, Forbes announces its annual Midas List of the top VC investors in the world. Nisa has been on the list for four consecutive years, ranking No.61 and up 12 places from last year.

  8. Show article details.

    BRIEF-Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program

    Reuters – 7:35 AM ET 04/12/2022

    Schrodinger Inc (SDGR): * SCHRÖDINGER REPORTS NEW PRECLINICAL DATA SUPPORTING ADVANCEMENT OF ITS WEE1 INHIBITOR PROGRAM AT AMERICAN ASSOCIATION OF CANCER RESEARCH 2022 ANNUAL MEETING. * Schrodinger Inc (SDGR) - HIGHLY SELECTIVE AND STRUCTURALLY-DISTINCT WEE1 INHIBITORS DEMONSTRATE STRONG ANTI-TUMOR ACTIVITY IN TUMOR MODELS.

  9. Show article details.

    Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting

    Business Wire – 7:00 AM ET 04/12/2022

    Schrödinger’s Highly Selective and Structurally-Distinct Wee1 Inhibitors Demonstrate Strong Anti-Tumor Activity in Tumor Models On Track to Select a Wee1 Development Candidate in 2022 Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today presented new preclinical data from its Wee1 inhibitor program in a poster session ...

  10. Show article details.

    Qiming's Portfolio Company Rendu Biotechnology Lists on STAR Market

    PR Newswire – 10:18 PM ET 03/29/2022

    SHANGHAI, March 29, 2022 Qiming Venture Partners' portfolio company Rendu Biotechnology, a leader in RNA molecular diagnostics in China, today listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Qiming Venture Partners is the earliest investor in Rendu Biotechnology and led the company's Series A financing round in 2013.

  11. Show article details.

    Qiming's Portfolio Company Arrail Group Lists on Main Board of HKEX

    PR Newswire – 12:08 AM ET 03/22/2022

    SHANGHAI, March 22, 2022  Qiming Venture Partners' portfolio company Arrail Group, a leading dental services provider in China, today listed on the main board of Hong Kong Stock Exchange. As an early investor, Qiming Venture Partners first invested in Arrail Group in 2010 and followed on in the company's Series A, B and C rounds.

  12. Show article details.

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 8:30 AM ET 03/17/2022

    Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on March 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 42,425 shares of the company’s common stock to 17 newly hired employees, including seven newly hired employees based in India.

  13. Show article details.

    Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022

    Business Wire – 4:35 PM ET 03/08/2022

    Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its small-molecule Wee1 inhibitors will be presented during a poster session at the American Association of Cancer Research Annual Meeting taking place in New Orleans, Louisiana, April 8-13, 2022.

  14. Show article details.

    Qiming Venture Partners Welcomes David Chu as IR Partner

    PR Newswire – 8:00 PM ET 03/01/2022

    SHANGHAI, March 1, 2022 Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that David Chu has joined the firm as a Partner, focusing on fundraising and investor relations for Qiming's USD funds. David has extensive experience in fund management and investment.

  15. Show article details.

    Schrödinger to Present at Truist Securities Life Sciences AI Symposium - Biotech & Tools

    Business Wire – 4:30 PM ET 02/28/2022

    Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at the Truist Securities Life Sciences AI Symposium - Biotech & Tools.

  16. Show article details.

    BRIEF-Schrödinger Reports Results For Q4 And Full Year 2021

    Reuters – 4:57 PM ET 02/24/2022

    Schrodinger Inc (SDGR): * SCHRÖDINGER REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. * SEES FY REVENUE UP 17 TO 31 PERCENT. * SEES FY REVENUE $161 MILLION TO $181 MILLION. * QTRLY TOTAL REVENUE $46.2 MILLION VERSUS $33 MILLION. * SEES ONGOING GROWTH IN ADOPTION AND SCALE UP OF SOFTWARE PLATFORM, WITH TARGET ACV GROWTH OF OVER 20 PERCENT IN 2023.

  17. Show article details.

    Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021

    Business Wire – 4:01 PM ET 02/24/2022

    Delivered Strong Fourth Quarter, with Software Revenue of $38.6 Million, a 55 Percent Increase over Fourth Quarter of 2020 Full Year 2021 Total Revenue of $137.9 Million, up 28 Percent Year-over-Year, with Full Year 2021 Software Revenue of $113.2 Million, up 22 Percent Year-over-Year Provides Financial Outlook for 2022 and Outlines Key Strategic Goals for 2022-2023 NEW YORK---- Schrödinger, In...

Page:

Today's and Upcoming Events

  • Aug
    10

    SDGR to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    04

    SDGR announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.